MedTrace Logo

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 408

Last updated 2026-05-14

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of surovatamig (formerly AZD0486) administered as monotherapy or in combination with other anticancer agents in participants with hematological malignancies

Conditions

Interventions

DRUG

Surovatamig

Surovatamig will be administered as either SC injection or IV infusion.

DRUG

Prednisone (or equivalent)

Prednisone (or equivalent) will be administered either oral or IV infusion as per standard of care.

DRUG

Rituximab

Rituximab will be administered as IV infusion as per standard of care.

DRUG

Cyclophosphamide

Cyclophosphamide will be administered as IV infusion as per standard of care.

DRUG

Vincristine

Vincristine will be administered as IV infusion as per standard of care.

DRUG

Doxorubicin

Doxorubicin will be administered as IV infusion as per standard of care.

DRUG

Acalabrutinib

Acalabrutinib will be administered orally

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-30
Primary Completion
2028-02-28
Completion
2029-06-11
FDA Drug
Yes

Countries

  • United States
  • Australia
  • China
  • Czechia
  • Denmark
  • France
  • Germany
  • Italy
  • Japan
  • South Korea
  • Spain
  • Taiwan
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06564038 on ClinicalTrials.gov